Form 6-K GLAXOSMITHKLINE PLC For: May 06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
GSK announces changes to its Board and Committees
GlaxoSmithKline plc today announces the following changes to its
Board and Committee membership effective 6 May 2021.
As previously announced, Dr Anne Beal has joined the Board as an
Independent Non-Executive Director. She has been appointed a member
of the Corporate Responsibility Committee.
In addition, Charles Bancroft has been appointed a member of the
Nominations & Corporate Governance and Science Committees.
These appointments are in addition to his role as Chairman of the
Audit & Risk Committee and membership of the Transformation
& Separation Committee.
Note
1.
|
From 6 May 2021 the Board of GSK comprises
|
|
|
Sir Jonathan Symonds
Emma
Walmsley
Iain
Mackay
Dr Hal Barron
Vindi Banga
Charles Bancroft
Dr Anne Beal
Dr Vivienne
Cox
Lynn
Elsenhans
Dr Jesse Goodman
Dr Laurie Glimcher
Urs
Rohner
|
Non-Executive Chairman
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer and President, R&D
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
|
V A Whyte
Company Secretary
6 May 2021
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
06, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK (GSK) call put ratio 12 calls to 1 put with focus on April weekly (26) 41 calls
- Perelel Launches 'Fertility, Unfiltered' Series With Whitney Port To Champion Raw Motherhood Narratives to Break the Silence on Infertility and Loss and Teams Up With Baby Quest To Sponsor One Woman's
- DIVIDEND 15 SPLIT CORP. Monthly Dividend Declaration for Class A & Preferred Share
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!